Physician profile
Barbara Seligman
NPI 1194783498
$2,243.28
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,140 · 2020: $103.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $525.08 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $323.78 | 2019 | |
| Janssen Biotech, INC. | $251.12 | 2019 | |
| Lilly USA, LLC | $195.82 | 2019 | |
| Tesaro, INC. | $172.80 | 2019 | |
| Amgen INC. | $145.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $129.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.59 | 2019 | |
| Pfizer INC. | $114.28 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.55 | 2019 | |
| Merck Sharp & Dohme LLC | $58.85 | 2019 | |
| Verastem, INC. | $52.50 | 2019 | |
| Genzyme Corporation | $22.73 | 2019 | |
| Janssen Scientific Affairs, LLC | $20.79 | 2019 | |
| Clovis Oncology, INC. | $19.51 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $15.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Seligman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.